Cerebrolysin
Cerebrolysin
A parenteral nootropic drug consisting of low molecular weight peptides and amino acids derived from porcine brain tissue. Used clinically for stroke, TBI, and dementia treatment.
Typical Cost
$300-600 for 4-week course
Status
Research
Peptide Profile
Cerebrolysin
Mechanism of Action
Provides neurotrophic support, enhances neuroplasticity, reduces neuroinflammation, and promotes neuronal survival. Contains neurotrophic factors that cross blood-brain barrier.
Common Dosages
intramuscular
2-10ml
Daily or 3-5x weekly · 4-6 weeks
intravenous
10-30ml
Daily · 10-14 days
Benefits
Cognitive enhancement
Stroke recovery
Dementia symptom management
Neuroprotection
TBI recovery
Improved memory and focus
Side Effects
Injection site reactions
Mild dizziness
Headache
Nausea (rare)
Allergic reactions (rare)
Key Research
Cerebrolysin in Alzheimer's disease
Meta-analysis showed significant improvement in cognitive function and global clinical status
Cerebrolysin in acute ischemic stroke
Improved neurological recovery when administered within 24 hours of stroke onset
Regulatory Status
Approved in over 50 countries for dementia, stroke, and TBI. Not FDA-approved in US. Available by prescription in many countries.
Contraindications
- ⚠Pregnancy/breastfeeding
- ⚠Severe kidney disease
- ⚠History of seizures
- ⚠Allergies to porcine products
GLP-1 users concerned about cognitive health may consider cerebrolysin alongside SeraVia Vitality+ Multi for comprehensive brain support.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.